Literature DB >> 23452745

Mechanisms of thrombosis in cancer.

Anna Falanga1, Laura Russo, Cristina Verzeroli.   

Abstract

Patients with cancer are at high risk of developing thrombosis. The pathogenesis of blood coagulation activation in cancer patients is complex involves both clinical and biological factors. The thrombotic risk varies according to the type of malignancy and its disease stage, and is increased by concomitant patient-related thrombotic risk factors (i.e. advanced age, infection, heart disease). In addition, the tumor cell-specific prothrombotic properties and the host cell inflammatory response dramatically contribute to the risk of thrombosis in these patients. The current development of risk assessment models to predict thrombosis in cancer is important for identifying high-risk patients and predispose the adequate preventive measures. In this review we provide an overview of the principal mechanisms of thrombosis in cancer, including clinical and biological risk factors, and a summary of risk assessment tools to predict thrombosis in the single patient.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23452745     DOI: 10.1016/S0049-3848(13)70024-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  24 in total

1.  Predictors of unknown cancer in patients with ischemic stroke.

Authors:  Sonia Quintas; Jacobo Rogado; Pedro Gullón; Vilma Pacheco-Barcia; Julio Dotor García-Soto; Gemma Reig-Roselló; Rebeca Mondéjar; Ramón Colomer; Jose Vivancos
Journal:  J Neurooncol       Date:  2018-01-08       Impact factor: 4.130

Review 2.  Venous thrombosis and cancer: from mouse models to clinical trials.

Authors:  Y Hisada; J E Geddings; C Ay; N Mackman
Journal:  J Thromb Haemost       Date:  2015-06-26       Impact factor: 5.824

Review 3.  The coagulome and the oncomir: impact of cancer-associated haemostatic dysregulation on the risk of metastasis.

Authors:  Kate Burbury; Michael P MacManus
Journal:  Clin Exp Metastasis       Date:  2018-02-28       Impact factor: 5.150

4.  Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism.

Authors:  Ambarina S Faiz; Imran Khan; Michele G Beckman; Paula Bockenstedt; John A Heit; Roshni Kulkarni; Marilyn Manco-Johnson; Stephan Moll; Thomas L Ortel; Claire S Philipp
Journal:  Thromb Res       Date:  2015-07-05       Impact factor: 3.944

Review 5.  Thrombosis in leukemia: incidence, causes, and practical management.

Authors:  Patricia Guzmán-Uribe; Ángel Gabriel Vargas-Ruíz
Journal:  Curr Oncol Rep       Date:  2015       Impact factor: 5.075

6.  Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.

Authors:  Federica Martella; Marco Cerrano; Daniela Di Cuonzo; Carolina Secreto; Matteo Olivi; Vincenzo Apolito; Stefano D'Ardia; Chiara Frairia; Valentina Giai; Giuseppe Lanzarone; Irene Urbino; Roberto Freilone; Luisa Giaccone; Alessandro Busca; Chiara Maria Dellacasa; Ernesta Audisio; Dario Ferrero; Eloise Beggiato
Journal:  Ann Hematol       Date:  2022-02-07       Impact factor: 3.673

7.  Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Abdullah K Alahmari; Ziyad S Almalki; Ahmed K Alahmari; Jeff J Guo
Journal:  Am Health Drug Benefits       Date:  2016-06

Review 8.  Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management.

Authors:  E Donnellan; B Kevane; B R Healey Bird; F Ni Ainle
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

Review 9.  Are MPNs vascular diseases?

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

10.  ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.

Authors:  Kyungho Kim; Jing Li; Andrew Barazia; Alan Tseng; Seock-Won Youn; Giovanni Abbadessa; Yi Yu; Brian Schwartz; Robert K Andrews; Victor R Gordeuk; Jaehyung Cho
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.